Recipharm’s $22.3M blow-fill-seal expansion now operational at Kaysersberg, France, plant

Recipharm
The plant manufactures single-dose units and has an advanced aseptic process for sterile liquid packaging applications. (Recipharm)

Recipharm, a Swedish CDMO, said the new blow-fill-seal equipment that was part of the company’s $22.3 million (€18 million) investment at its Kaysersberg, France, facility is now operational.

The project added a new blow-fill-seal high-speed filling and packaging line, giving the facility a total of eight lines and increasing the plant’s manufacturing capacity by 200 million unidoses a year.

The plant manufactures single-dose units and has an advanced aseptic process for sterile liquid packaging applications. 

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The construction project added 2,400 square meters to the facility, providing room for three machines that will eventually let Recipharm produce more than 1.2 billion unidoses a year.

“We have worked hard to develop a flexible service that can cater for even the most complex of projects,” Yves Buelens, general manager of the plant, said in a statement. “Adding the line to our facility will allow us to take on new customer projects more quickly, as well as continue to meet our current customers’ requirements. The additional space we’ve added also means we are also well positioned for further growth in line with future customer demand.”

Recipharm acquired the facility from Novartis’ Alcon unit for $19.7 million in 2015. 

Suggested Articles

Generic pain drug maker Lannett is closing its plant in Wyoming and laying off the remaining 80 employees.

Turkey is getting its first locally produced mAb via an Iranian biosimilars marker and the $100 million plant it built there.

Teva is recalling 10 more lots of losartan as blood pressure drugs tainted with suspected carcinogens continue to pop up in the U.S. supply chain.